RLT-PSMA
Radioligand therapy prostate-specific membrane antigen
Advertisement
Results of the BOP trial have shown 64Cu SAR-Bombesin can detect lesions in BCR prostate cancer that is PSMA PET-negative.
SNMMI convened an autonomous workgroup to review prospective phase 2/3 clinical trials that used 177Lu-PSMA-617.
A PSA decrease ≥30% after the first 2 cycles of 177Lu PSMA can serve as an early marker of response in clinical practice.
The National Comprehensive Cancer Network now includes POSLUMA in its clinical practice guidelines for prostate cancer.
[18F]DCFPyL impacted patient management in 44% of patients vs 29% of patients who received [18F]fluoromethylcholine.
The VISION trial assigned patients to receive either [177Lu]Lu-PSMA-617 plus standard of care or standard of care alone.
Patients treated with enzalutamide prior to Lu-PSMA therapy had higher mean SUV values before treatment with 18 F-DCFPyL.
68Ga-PSMA-11 and FDG-PET/CT scans were compared with scans from the VISION trial to assess patient eligibility for Pluvicto.
The care management plans for several patients were changed after those patients underwent PSMA PET/CT.
A research team developed a study to implement aPROMISE for the evaluation of PSMA and FDG-PET/CT scans acquired before RLT.
A team of researchers compiled optimized methods for post-treatment radiation precautions for patients receiving Pluvicto.
New research identified genomic features and post-therapeutic SPECT/CT parameters as predictors of response to Pluvicto.
A study compared bone marrow dosimetry using three different methods for patients treated with 177Lu-PSMA-617.
Dr. Brian Helfand details the purpose of 18F-rhPSMA-7.3 and how it compares to other PSMA PET radiopharmaceuticals.
PROPELLER: Assessing a Novel Imaging Agent in Patients With Intermediate-, High-Risk Prostate Cancer
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.POSLUMA is a diagnostic imaging agent for the PET detection of PSMA-positive lesions in patients with prostate cancer.
Researchers developed an antibody-drug conjugate and immuno-PET agent based on the YS5 antibody for high CD46.
Researchers found 18F-rhPSMA-7.3 to have a high affinity and potential for low bladder activity.
When testing interaction with the use of MDT, patients with positive PSMA PET not receiving MDT had a higher risk of CR.
The FDA has granted Fast Track designation to 177Lu-PNT2002 for the treatment of patients with mCRPC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.